SCG2
Secretogranin-2
Also known as: CHGC, SCG2_HUMAN, SgII, SN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P13521
- Gene
- SCG2
- Ensembl
- ENSG00000171951
- Chromosome
- 2
- Canonical length
- 617 aa
- Protein class
- Plasma proteins, Predicted secreted proteins
- Subcellular location
- Golgi apparatus,Vesicles
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene is a member of the chromogranin/secretogranin family of neuroendocrine secretory proteins. Studies in rodents suggest that the full-length protein, secretogranin II, is involved in the packaging or sorting of peptide hormones and neuropeptides into secretory vesicles. The full-length protein is cleaved to produce the active peptide secretoneurin, which exerts chemotaxic effects on specific cell types, and EM66, whose function is unknown. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
617 residues, UniProt reviewed canonical sequence.
>P13521|SCG2
1 MAEAKTHWLG AALSLIPLIF LISGAEAASF QRNQLLQKEP DLRLENVQKF PSPEMIRALE
61 YIENLRQQAH KEESSPDYNP YQGVSVPLQQ KENGDESHLP ERDSLSEEDW MRIILEALRQ
121 AENEPQSAPK ENKPYALNSE KNFPMDMSDD YETQQWPERK LKHMQFPPMY EENSRDNPFK
181 RTNEIVEEQY TPQSLATLES VFQELGKLTG PNNQKRERMD EEQKLYTDDE DDIYKANNIA
241 YEDVVGGEDW NPVEEKIESQ TQEEVRDSKE NIEKNEQIND EMKRSGQLGI QEEDLRKESK
301 DQLSDDVSKV IAYLKRLVNA AGSGRLQNGQ NGERATRLFE KPLDSQSIYQ LIEISRNLQI
361 PPEDLIEMLK TGEKPNGSVE PERELDLPVD LDDISEADLD HPDLFQNRML SKSGYPKTPG
421 RAGTEALPDG LSVEDILNLL GMESAANQKT SYFPNPYNQE KVLPRLPYGA GRSRSNQLPK
481 AAWIPHVENR QMAYENLNDK DQELGEYLAR MLVKYPEIIN SNQVKRVPGQ GSSEDDLQEE
541 EQIEQAIKEH LNQGSSQETD KLAPVSKRFP VGPPKNDDTP NRQYWDEDLL MKVLEYLNQE
601 KAEKGREHIA KRAMENMLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SCG2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.63
- Highest tissue expression
- 392 nTPM
Expression across tissuesHPA
Tissue
- hypothalamus: 392 nTPM
- adrenal gland: 340 nTPM
- pituitary gland: 267 nTPM
- basal ganglia: 262 nTPM
- cerebral cortex: 141 nTPM
- midbrain: 91 nTPM
Single-cell type
- pancreatic islet cells: 2,078 nCPM
- corticotrophs: 1,185 nCPM
- adrenal medulla cells: 691 nCPM
- other brain neurons: 346 nCPM
- gonadotrophs: 341 nCPM
- neuroendocrine cells: 281 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hypothalamus: 948 nTPM
- pons: 553 nTPM
- midbrain: 422 nTPM
- thalamus: 293 nTPM
- medulla oblongata: 269 nTPM
- spinal cord: 186 nTPM
ReferencesPubMed · IEDB
Publications for SCG2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1 publication
- Lymphocytic hypophysitis: report of two biopsy-proven cases and one suspected case with pituitary autoantibodies.
2007 · J Endocrinol Invest · RCR 1.1 · 37 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.85
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.08
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- angiogenesis
- endothelial cell migration
- eosinophil chemotaxis
- induction of positive chemotaxis
- inflammatory response
- intracellular signal transduction
- MAPK cascade
- negative regulation of endothelial cell apoptotic process
- negative regulation of endothelial cell proliferation
- negative regulation of extrinsic apoptotic signaling pathway
- positive chemotaxis
- positive regulation of endothelial cell proliferation
- protein secretion
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SCG2 as an antibody target. Whether an autoantibody or antibody against SCG2 could matter depends on whether native SCG2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SCG2 is annotated as secreted, so native SCG2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label SCG2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...